Licab Tablet contains Lithium Carbonate 300 mg, a mood stabilizer primarily indicated for the treatment and management of bipolar disorder, including acute manic episodes and maintenance therapy to prevent recurrence of mania and depression. Lithium carbonate modulates neurotransmitter activity and intracellular signaling pathways, contributing to mood stabilization. This medication is also utilized off-label for augmentation in treatment-resistant depression. Licab Tablet should be administered under strict medical supervision, with dosage individualized based on clinical response and serum lithium levels, which require regular monitoring due to the narrow therapeutic index. Common side effects include gastrointestinal disturbances, polyuria, tremor, and mild cognitive effects, while serious adverse reactions may involve renal impairment, hypothyroidism, and lithium toxicity manifesting as severe tremors, confusion, or ataxia. Patients should maintain adequate hydration and avoid concurrent use of nephrotoxic agents or nonsteroidal anti-inflammatory drugs (NSAIDs) unless advised by a healthcare professional. Regular monitoring of renal and thyroid function, as well as electrolyte levels, is essential during therapy. Licab Tablet is contraindicated in patients with significant renal or cardiovascular disease and should be used cautiously during pregnancy and lactation. Patient education on adherence and recognition of toxicity symptoms is critical to ensure safe and effective treatment outcomes.